Marker Therapeutics, Inc.
Publicly observedHouston, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Houston | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Marker Therapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | CK3KR85CSP23 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Sept 2024Publicly observed
NIH SBIR/STTR award: A Phase 1 Study of Patient-Derived Multi-Tumor Associated Antigen Specific T Cells (MT-601) Administered to Patients with Metastatic Pancreatic Cancer following frontline FOLFIRINOX
USD 674,275.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Aug 2024Publicly observed
NIH SBIR/STTR award: A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma
USD 665,000.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Aug 2024Publicly observed
NIH SBIR/STTR award: A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed Non-Hodgkin Lymphoma
USD 665,000.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant14 Jun 2024Publicly observed
NIH SBIR/STTR award: Controlling Tumor Immune Escape in Pancreatic Cancer using a Dual T Cell Product Strategy
USD 1,348,474.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant10 Aug 2023Publicly observed
NIH SBIR/STTR award: Phase 2 clinical trial of a novel T cell therapy following bridging therapy with hypomethylating agents for relapsed AML patients post-stem cell transplant
USD 664,838.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.